REFERENCES
- Kuwajima I, Ozawa T, Suzuki Y, Pharmacokinetic study of CS-905 (azelnidipine) in elderly patients with essential hypertension. J Clin Ther Med 2000; 16:375–387.
- Kuramoto K, Ichikawa S, Hirai A, Kanada S, Nakachi T, Ogihara T. Azelnidipine and amlodipine: A comparison of their pharmacokinetics and effects on ambulatory blood pressure. Hypertens Res 2003;26:201–208.
- Zou JJ, Ji HJ, Zhou XH, Zhu YB, Fan HW, Xiao DW, Hu Q. Determination of azelnidipine by LC-ESI-MS and its application to a pharmacokinetic study in healthy Chinese volunteers. Pharmazie 2008;63:568–570.
- Oizumi K, Nishino H, Koike H, Sada T, Miyamoto M, Kimura T. Antihyper- tensive effects of CS-905, a novel dihydropyridine Ca++ channel blocker. Jpn J Pharmacol 1989;51:57–64.
- Eguchi K, Kario K, Shimada K. Differential effects of a long-acting angiotensin converting enzyme inhibitor (temocapril) and a long-acting calcium antagonist (amlodipine) on ventricular ectopic beats in older hypertensive patients. Hypertens Res 2002;25:329–333.
- Biston P, Melot C, Degaute JP, Clement D, Quoidbach A. Prolonged antihypertensive effect of amlodipine: a prospective double-blind randomized study. Blood Press 1999;8:43–48.
- Wellington K, Scott JL. Azelnidipine. Drugs 2003;63:2613–2621.
- Shokoji T, Fujisawa Y, Kiyomoto H, Rahman M, Sun GP, Fan YY, Kimura S, Kohno M, Abe Y, Nishiyama A. Effect of a new calcium channel blocker, azelnidipine, on systemic hemodynamics and renal sympathetic nerve activity in spontaneously hypertensive rats. Hypertens Res 2005;28:1017–1023.
- Konno S, Hirooka Y, Araki S, Koga Y, Kishi T, Sunagawa K. Azelnidipine decreases sympathetic nerve activity via antioxidant effect in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 2008;52:555–560.
- Fujisawa M, Yorikane R, Chiba S, Koike H. Chronotropic effects of azelnidipine, a slow- and long-acting dihydropyridine-type calcium channel blocker, in anesthetized dogs: a comparison with amlodipine. J Cardiovasc Pharmacol 2009;53:325–332.
- Arita M, Hashizume T, Tanigawa K, Yamamoto H, Nishio I. A new Ca-antagonist, azelnidipine, reduced blood pressure during exercise without augmentation of sympathetic nervous system in essential hypertension: a randomized, double-blind, placebo-controlled trial. J Cardiovasc Pharmacol 1999;33:186–192.
- Yamagishi T. Efficacy of azelnidipine on home blood pressure and pulse rate in patients with essential hypertension: comparison with amlodipine. Hypertens Res 2006;29:767–773.
- Nakano K, Egashira K, Ohtani K, Gang Z, Iwata E, Miyagawa M, Sunagawa K. Azelnidipine has anti-atherosclerotic effects independent of its blood pressure- lowering actions in monkeys and mice. Atherosclerosis 2008;196:172–179.